ATLANTA, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of inoffice, accessible, and innovative therapeutic and diagnostic products, announces the onboarding of the first infertility medical clinic customers to offer its FemaSeed infertility treatment to patients in California and Florida. "Femasys has begun partnering with infertility centers across the United States, enab ...

ATLANTA, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of inoffice, accessible, and innovative therapeutic and diagnostic products, announces that the Company has secured strategic distribution partnerships for its CE-marked products, including FemaSeed® and FemVue® in Spain. Comercial Medico Quirurigca, SA (CMQ) will distribute the products in northern Spain and Durgalab ...

Femasys Inc. (FEMY) recently received 510(k) clearance from the FDA for FemChec, a diagnostic device for fallopian tube assessment. The device offers controlled delivery of contrast, confirming tubal status safely and efficiently. Femasys has achieved U.S. FDA clearance and Canadian regulatory approval for FemChec, a diagnostic solution designed for the controlled delivery of natural contrast during ultrasound evaluations of fallopian tubes. The device uses an alternating saline and air pattern to assist in ...

ATLANTA, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of inoffice, accessible, and innovative therapeutic and diagnostic products, today announced it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for FemChec®, an innovative diagnostic solution for checking the fallopian tubes, designed for controlled delivery of contrast for confi ...

ATLANTA, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of inoffice, accessible, and innovative therapeutic and diagnostic products, announces that the Company will be exhibiting at the Canadian Fertility and Andrology Society's (CFAS) 70th Annual Meeting, to be held September 12-14, 2024 at The Westin Bayshore, Vancouver, British Columbia. The Company will be exhibiting at ...

Femasys Inc. (FEMY) has announced that it has received the CE mark certification and Health Canada approval for its latest innovation, the FemVue MINI. This compact and environmentally conscious device is designed for fallopian tube assessment, offering the same high efficacy as its predecessor with a reduced ecological footprint. This milestone marks a significant step forward in Femasys' mission to provide accessible and sustainable healthcare solutions for women. FEMY is a leading biomedical company comm ...

ATLANTA, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of inoffice, accessible, and innovative therapeutic and diagnostic products, announces that Kathy Lee-Sepsick, Founder, President, and CEO, will participate in a fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference. The fireside chat will be hosted by Emily Bodnar, Life Sciences Analyst. The co ...

ATLANTA, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of inoffice, accessible and innovative therapeutic and diagnostic products, announces that it has received CE mark certification and product approval from Health Canada, the Public Health Agency of Canada, for its compact, eco-friendly FemVue® MINI for fallopian tube assessment. "Our mission at Femasys has always been to ...

ATLANTA, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of inoffice, accessible, and innovative therapeutic and diagnostic products, hosted Congresswoman Lucy McBath, Georgia's 7th district representative to the U.S. House of Representatives, for an informative tour of the Company's facility headquartered in Suwanee, Georgia. Femasys Founder, President and Chief Executive Of ...

Femasys Inc. (FEMY) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.22 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -16.67%. A quarter ago, it was expected that this company would post a loss of $0.22 per share when it actually produced a loss of $0.17, delivering a surprise of 22.73%. Over the last four quarters, the company has surpasse ...